Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

December 31, 2013

Conditions

HepatitisHepatitis C

Interventions

DRUG

Algeron

1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously

DRUG

PegIntron

1.5 μg/kg/week subcutaneously in combination with ribavirin

DRUG

Ribavirin

800-1400 mg/day orally

Trial Locations (1)

Moscow State University of Medicine and Dentistry, Moscow